The PASSAGE Program: a structured multicomponent interdisciplinary group intervention for the self-management of fibromyalgia.

Multicomponent interdisciplinary group intervention for self-management of fibromyalgia: a mixed-methods randomized controlled trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN14526380

Enrollment

Registered

2014-07-23

Start date

2009-09-01

Completion date

Unknown

Last updated

2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fibromyalgia syndrome (FMS), chronic pain Musculoskeletal Diseases Fibromyalgia

Interventions

1. Intervention group : The PASSAGE program is a structured multicomponent interdisciplinary group intervention aimed at reducing FMS symptoms and maintaining optimal function through the use of self-

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged 18 years or older 2. Had a medical diagnosis of FMS based on the American College of Rheumatology (ACR) classification criteria for at least 6 months 3. Reported pain of at least moderate intensity (at least 4/10) in the seven days prior to enrolment 4. Were motivated to attend all group sessions and to integrate the proposed self-management strategies 5. Agreed to not introduce new medications or treatments/therapies over the course of the PASSAGE program

Exclusion criteria

Exclusion criteria: 1. Subjects who presented pain-related symptoms commonly associated with FMS (e.g., irritable bowel syndrome, migraine) 2 Those who suffered from chronic pain syndromes other than FMS (e.g., painful diabetic neuropathy) 3. Physical/psychiatric disorders that could compromise their participation in the study

Design outcomes

Primary

Measure	Time frame
Pain intensity. Pain intensity was measured with a standardized numerical rating scale (NRS)	—

Secondary

Measure	Time frame
1. Severity of FMS (Fibromyalgia Impact Questionnaire) 2. Pain interference (Brief Pain Inventory) 3. Impact of pain on sleep quality (Chronic Pain Sleep Inventory) 4. Pain coping strategies and (Coping Strategy Questionnaire) 5. Tendency to catastrophize (Pain Catastrophizing Scale) 6. Depressive symptoms (The Beck Depression Inventory) 7. Health-related quality of life (SF-12v2) 8. Patient global impression of change (PGIC) 9. Perceived pain relief (0 to 100% Pain Relief Scale) Quantitative data were collected in both study groups at baseline (T0), after the intervention group completed the 8 sessions of the PASSAGE Program (T1), and 3 months later (T2). In order to document and further capture the intervention group patients? experiences, face-to-face open ended group narrative qualitative interviews were conducted 6 to 9 months after completion of the PASSAGE Program.	—

Measure

Time frame

1. Severity of FMS (Fibromyalgia Impact Questionnaire) 2. Pain interference (Brief Pain Inventory) 3. Impact of pain on sleep quality (Chronic Pain Sleep Inventory) 4. Pain coping strategies and (Coping Strategy Questionnaire) 5. Tendency to catastrophize (Pain Catastrophizing Scale) 6. Depressive symptoms (The Beck Depression Inventory) 7. Health-related quality of life (SF-12v2) 8. Patient global impression of change (PGIC) 9. Perceived pain relief (0 to 100% Pain Relief Scale) Quantitative data were collected in both study groups at baseline (T0), after the intervention group completed the 8 sessions of the PASSAGE Program (T1), and 3 months later (T2). In order to document and further capture the intervention group patients? experiences, face-to-face open ended group narrative qualitative interviews were conducted 6 to 9 months after completion of the PASSAGE Program.

—

Countries

Canada

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 4, 2026